LIPAGLYN - The novel drug for treating Diabetic Dyslipidemiacombines lipid and glucose lowering effects in one single molecule.
Lipaglyn™ is the first Glitazar to be approved and is the first New Chemical Entity (NCE)
discovered and developed indigenously by an Indian Pharma Company.
Lipaglyn™, is a novel drug targeted at bridging an unmet healthcare need for treating Hypertriglyceridemia or Diabetic Dyslipidemia in type 2 diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn™ is the first Glitazar to be approved anywhere in the world.
Lipaglyn™ is a prescription drug, currently available for sale in India only.
Discovered by the Zydus Research Centre, the dedicated NCE research arm of the Zydus group, Lipaglyn™ is a best-in-class innovation, designed to have a unique cellular mechanism of action following an extensive structure-activity relationship study initiated in the year 2000. Lipaglyn™ has a predominant affinity to PPAR alpha isoform and moderate affinity to PPAR gamma isoform of PPAR nuclear receptor sub-family. The molecule has shown beneficial effects on lipids and glycemic control without side effects. This molecule underwent extensive pre-clinical characterisation and the Investigational New Drug (IND) was submitted in the year 2004.
Zydus will offer a dedicated Lipaglyn™ support programme to patients and caregivers. The programme shall provide important support and information regarding access, adherence, education and thereby help patients to start and appropriately manage their disease and therapy over time.